Hormonal
Tirzepatide 15mg is associated with a higher risk of hypoglycemia compared to GLP-1 receptor agonists, although it has a lower risk of hypoglycemia compared to basal insulins.
If you are on the 15mg dose of Tirzepatide, especially if you also take insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) is higher than if you were on a standard GLP-1 drug like semaglutide. Monitor your blood sugar closely and discuss dose adjustments with your doctor if you experience symptoms of low blood sugar.
TZP 15mg was associated with more hypoglycemia than GLP-1 RAs (pooled RR=3.83, 95%CI [1.19-12.30], P=0.02)... TZP had lower odds of hypoglycemia compared to glargine (pooled RR=0.40, 95%CI [0.31-0.51], P<0.00001) and degludec (pooled RR=0.21, 95%CI [0.11-0.38], P<0.00001)
Why this rating
Based on pooled RCT data, though the authors note controversy and potential confounding from combination therapies.
Source
A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Zhuqing Meng et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1121387
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →